https://www.selleckchem.com/pr....oducts/GSK1904529A.h
8 years and 72% had heart-lung transplantation. PAH was usually idiopathic (65%) or due to congenital heart disease (25%). HPAP implementation resulted in the following significant benefits Decreased cumulative incidence of waitlist death within 1 and 2 years (p 0.0001); increased cumulative incidence of transplantation within 6 months, from 44% to 67% (p 0.01); and improved survival after listing (at 1, 3, and 5 years 61%, 50%, and 44% vs. 92%, 84%, and 72% before and after HPAP implementation, respectively; p = 0.02). HP
Curtir
Comentario
Compartilhar
